Reports Q4 revenue $40.1M, consensus $37.35M. "Our fourth quarter closes the books on a remarkable year for Silk Road Medical," said Erica Rogers, President and CEO. "We are well positioned to drive strong growth and category leadership while building upon the operating leverage we began to see in 2022."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SILK:
- Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook
- Silk Road Medical to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
- Silk Road Medical downgraded to Peer Perform from Outperform at Wolfe Research
- Silk Road Medical price target raised to $70 from $60 at Argus
